Voyager Therapeutics Names Alfred Sandrock, Jr CEO, Succeeding Michael Higgins

Voyager Therapeutics, Inc. (VYGR), a gene therapy company, announced Tuesday the appointment of Alfred Sandrock, Jr. as chief executive officer. Sandrock succeeds Michael Higgins, who served as interim CEO since June 2021, and continues to serve as Chairman of the Voyager Board of Directors.

Sandrock was appointed to the Voyager Board of Directors in February 2022, following 23 years at Biogen where he identified and developed novel therapies for a variety of serious diseases.

He served as chief medical officer at Biogen and was ultimately appointed head of research and development.

Higgins said, "His success pioneering the development of numerous innovative neurological treatments, and particularly, his skill in advancing promising candidates from early-stage research toward clinical proof of concept, is perfectly suited for Voyager. He is the ideal leader to amplify the impact of our proprietary TRACERTM AAV capsids that we believe can overcome many of the limitations of first-generation AAV gene therapy and create meaningful therapeutics for patients."

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
United Airlines and Archer Aviation Inc. announced plans to launch the first commercial electric air taxi route in Chicago, between O'Hare International Airport or ORD and Vertiport Chicago. As part of their urban air mobility or UAM network buildout, both companies will utilize Archer's electric vertical takeoff and landing or eVTOL aircraft in the new route. Fort Wayne, Indiana-based Perfection Bakeries D/B/A Aunt Millie's is recalling 8 ct. packages of Our Family White Hot Dog Buns citing the possible presence of undeclared sesame, a known allergen, the U.S. Food and Drug Administration said. The product comes in a printed plastic package marked with "Our Family Hot Dog Buns 8 ct." on the top and has a blue twist tie. Parsippany, New Jersey -based Ascend Laboratories LLC. is recalling Dabigatran Etcxilate capsules citing the detection of N-Nitrosodimethylamine or NDMA impurity, a probable human carcinogen, the U.S. Food and Drug Administration said. The product is used as an oral anticoagulant to lower the risk of stroke and blood clots.
Follow RTT